Matches 1 - 50 out of 86 1 2 >


Match Document Document Title
US20140205620 ENGINEERED RESPIRATORY SYNCYTIAL VIRUSES WITH CONTROL OF CELL-TO-CELL VIRUS TRANSMISSION FOR ENHANCED SAFETY OF LIVE VIRUS VACCINES  
Highly antigenic yet safe vaccines against diseases caused by Paramyxoviridae viruses such as respiratory syncytial virus (RSV) are provided. The vaccines comprise attenuated Paramyxoviridae...
US20120315295 Development of a Marker Foot and Mouth Disease Virus Vaccine Candidate That is Attenuated in the Natural Host  
We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus...
US20120195927 GM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS  
The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous...
US20150150961 COMPOSITIONS AND METHODS FOR RAPID IMMUNIZATION AGAINST DENGUE VIRUS  
Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be...
US20130323278 Chimeric Flavivirus Vaccines  
A chimeric live, infectious, attenuated virus containing a yellow fever virus, in which the nucleotide sequence for a prM-E protein is either deleted, truncated, or mutated, so that functional...
US20110086064 COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN  
Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of...
US20110280904 Generation of virus-like particles and use as panfilovirus vaccine  
In this application are described filovirus-like particles for both Ebola and Marburg and their use as a diagnostic and therapeutic agent as well as a filovirus vaccine. Also described is the...
US20120076820 CD40L VACCINES, COMPOSITIONS, AND METHODS RELATED THERETO  
The disclosure relates to vaccinating a subject against a viral infection, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the use of CD40L expressed...
US20130142824 NOVEL MODIFIED LIVE-ATTENUATED VACCINES (MLV) CREATED BY DNA SHUFFLING AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV)  
The present invention provides a novel infectious cDNA clone of porcine reproductive and respiratory syndrome virus (PRRSV), particularly for PRRSV strain VR2385; an improved DNA-launched reverse...
US20140271709 BOVINE VIRUS VACCINES THAT ARE LIQUID STABLE  
The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, and a sugar alcohol. The present invention also discloses the manufacture of such vaccines and...
US20140023679 LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE  
The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of...
US20110008282 IL-1alpha immunization induces autoantibodies protective against atherosclerosis  
Immunization of a mammal with IL-1α, which causes the mammal to generate IL-1α autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an...
US20140302088 COMPOSITIONS AND METHODS FOR DENGUE VIRUS CHIMERIC CONSTRUCTS IN VACCINES  
Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not...
US20110052630 Compositions and Methods Using Herpes Simplex Virus  
Provided herein are methods and compositions for use in treating HSV-related conditions and diseases.
US20150140035 AUTOLOGOUS BIOLOGICAL CANCER VACCINE  
The present disclosure relates to an autologous biological cancer vaccine and to a method for preparing the same. The vaccine of the present application is a biological vaccine obtained from...
US20140127261 Flavivirus Envelope Protein Mutations Affecting Virion Disassembly  
Mutations in the central monomer contact interface of the flavivirus envelope protein which modulate the infectivity of the flavivirus are made. The mutations decrease the ability of the envelope...
US20110159036 MVA expressing modified HIV envelope, GAG, and POL genes  
The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
US20130224243 USE OF HERPES VECTORS FOR TUMOR THERAPY  
Eliciting a systemic antitumor immune response can be efficacious for a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type. To this end a...
US20130071432 COMBINATION VIROTHERAPY FOR CANCER  
One aspect of the present disclosure relates to a method for treating a subject with cancer. The method includes administering an oncolytic virus simultaneously, sequentially, or separately in...
US20130224144 SEQUENTIAL ADMINISTRATION OF A REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION PROTOCOLS  
Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to...
US20110123567 RECOMBINANT RIFT VALLEY FEVER (RVF) VIRUSES AND METHODS OF USE  
Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse...
US20140050761 Crimean-Congo Hemorrhagic Fever Virus Vaccine  
The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism...
US20130034585 Bovine Herpes Virus Vaccine With Multiple Mutations  
A BHV-1 mutant virus has been made that incorporates into a single virus two or more deletions in one or more of three genes—glycoprotein N, glycoprotein E and Us9. Specifically, a BHV-1...
US20140017313 FORMULATIONS  
This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. beads, comprising a matrix material which matrix material...
US20130224235 POTATO VIRUS A COAT PROTEIN-BASED VACCINES FOR MELANOMA  
A vaccine for treating melanoma, comprising at least one melanoma antigen and a viral-like particle comprising potato virus A coat protein. Use of vaccine for treating melanoma, including protein...
US20110117126 ATTENUATED PESTIVIRUS  
The present invention relates to recombinant attenuated pestiviruses, in particular to recombinant attenuated CSFV, BVDV, or BDV, wherein said recombinant attenuated pestivirus does not produce a...
US20120201850 INFECTIOUS BOVINE VIRAL DIARRHEA VIRUS  
The invention belongs to the field of animal health and in particular Bovine Viral Diarrhea Virus (BVDV). The invention provides infectious BVDV clones and methods to produce said BVDV clones. The...
US20130251747 RECOMBINANT EQUINE HERPESVIRUS-1 VACCINE CONTAINING MUTATED GLYCOPROTEIN C AND USES THEREOF  
The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising...
US20090191149 IL-1alpha IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS  
Immunization of a mammal with IL-1α, which causes the mammal to generate IL-1α autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an...
US20100310601 Adeno-Associated Virus Materials and Methods  
The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV)...
US20120183574 MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCNATION OF NEONATES  
The invention concerns the use of a virus for the preparation of a medicament for the vaccination or treatment of a human, wherein the virus is capable of infecting the cells of the human, but not...
US20110159034 METHODS AND REAGENTS FOR VACCINATION WHICH GENERATE A CD8 T CELL IMMUNE RESPONSE  
New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes...
US20120328652 RECOMBINANT ATTENUATED PARVOVIRUS  
The invention is in the field of virus vaccines for protecting animals against infection by parvovirus, their production and use. More in particular, the invention is related to a vaccine...
US20130115244 Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant  
The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide...
US20130129780 MODIFIED INFECTIOUS LARYNGOTRACHEITIS VIRUS (ILTV) AND USES THEREOF  
Provided herein are modified infectious largotracheitis viruses (ILTVs) and methods of using the same. For example, provided are attenuated ILTVs. The attenuated ILTVs can be used to illicit...
US20130195914 Expression Of Positive Sense Single Stranded RNA Virus And Uses Thereof  
The invention relates to the fields of viruses, vaccines and compounds and methods for expression. In particular, the invention includes methods and agents capable of producing quantities of a...
US20140030290 Infectious Clones of RNA Viruses and Vaccines and Diagnostic Assays Derived Thereof  
An infectious clone based on the genome of a wild-type RNA virus is produced by the process of providing a host cell not susceptible to infection by the wild-type RNA virus, providing a...
US20110070262 Viral Vectors and Their Use in Therapeutic Methods  
The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
US20110159032 MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES  
The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at...
US20110027313 VIRAL RECOMBINEERING AND USES THEREOF  
The invention uses recombinant technology to create infectious molecular clones that capture the sequence diversity of viral genes found in natural populations of mixed genotype viruses, such as...
US20100215692 Dengue Chimeric Viruses  
The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes...
US20100323003 Flaviviridae Mutants Comprising a Deletion in the Capsid Protein for Use as Vaccines  
The present invention relates to a mutant virus of the family flaviviridae, comprising a deletion in the capsid protein of at least 20 successive amino acids, without any further deletion,...
US20110165230 ATTENUATED LIVE VACCINES  
Disclosed is an attenuated flavivirus live vaccine comprising a flavivirus mutant, characterised in that the flavivirus mutant has a deletion in the capsid protein of at least more than 4...
US20110268762 IMMUNIZATION OF AVIANS BY MUCOSAL ADMINISTRATION OF NON-REPLICATING VECTORED VACCINES  
The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to mucosal administration via aerosol spray to avians of...
US20110165189 RABIES VIRUS-BASED RECOMBINANT IMMUNOCONTRACEPTIVE COMPOSITIONS AND METHODS OF USE  
Described herein are recombinant rabies viruses comprising a heterologous nucleic acid sequence encoding an immunocontraceptive protein, such as gonadotropin-releasing hormone (GnRH) or zona...
US20100209454 ATTENUATED VIRUSES USEFUL FOR VACCINES  
This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions...
US20090246216 NOVEL ATTENUATED POLIOVIRUS  
A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and...
US20080279891 Viral Adjuvants  
The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine...
US20080175862 Recombinant Flavivirus Vaccines  
The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses...
US20080166372 Live Attenuated Rotavirus Vaccine for Oral Administration  
This invention provides liquid rotavirus formulations that are suitable for oral administration to human infants. In particular, the invention provides pharmaceutical compositions and vaccines,...

Matches 1 - 50 out of 86 1 2 >